These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

530 related items for PubMed ID: 34373422

  • 21. Hepatic failure associated with immune checkpoint inhibitors: An analysis of the Food and Drug Administration Adverse Event Reporting System database.
    Xu Y, Yan C, Zhao Y, Li D, Guo M, Cui X.
    Cancer Med; 2023 Apr; 12(8):9167-9174. PubMed ID: 36734333
    [Abstract] [Full Text] [Related]

  • 22. Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report.
    Tominaga K, Takeuchi K, Takakuma S, Sakamoto E, Hatanaka S, Kajimoto Y, Toda E, Terasaki Y, Kunugi S, Terasaki M, Shimizu A.
    BMC Nephrol; 2023 Mar 09; 24(1):48. PubMed ID: 36894873
    [Abstract] [Full Text] [Related]

  • 23. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
    Delasos L, Bazewicz C, Sliwinska A, Lia NL, Vredenburgh J.
    J Oncol Pharm Pract; 2021 Apr 09; 27(3):716-721. PubMed ID: 32723064
    [Abstract] [Full Text] [Related]

  • 24. Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: Four cases describing the clinical heterogeneity of central endocrine dysfunction.
    Hartmann A, Paparoupa M, Volkmer BG, Rompel R, Wittig A, Schuppert F.
    J Oncol Pharm Pract; 2020 Oct 09; 26(7):1774-1779. PubMed ID: 32164491
    [Abstract] [Full Text] [Related]

  • 25. A case of nivolumab-induced acute-onset type 1 diabetes mellitus in melanoma.
    Sakaguchi C, Ashida K, Yano S, Ohe K, Wada N, Hasuzawa N, Matsuda Y, Sakamoto S, Sakamoto R, Uchi H, Furue M, Nomura M, Ogawa Y.
    Curr Oncol; 2019 Feb 09; 26(1):e115-e118. PubMed ID: 30853818
    [Abstract] [Full Text] [Related]

  • 26. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
    Grimmelmann I, Momma M, Zimmer L, Hassel JC, Heinzerling L, Pföhler C, Loquai C, Ruini C, Utikal J, Thoms KM, Kähler KC, Eigentler T, Herbst RA, Meier F, Debus D, Berking C, Kochanek C, Ugurel S, Gutzmer R, German Dermatooncology Group (DeCOG).
    Eur J Cancer; 2021 May 09; 149():1-10. PubMed ID: 33812141
    [Abstract] [Full Text] [Related]

  • 27. Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.
    Fuu T, Iijima K, Kusama Y, Otsuki T, Kato H.
    J Med Case Rep; 2022 May 18; 16(1):193. PubMed ID: 35581611
    [Abstract] [Full Text] [Related]

  • 28. Acute-onset diabetes mellitus with ketoacidosis in a nivolumab-treated patient with hepatocellular carcinoma.
    Harsch IA, Konturek PC.
    Wiad Lek; 2018 May 18; 71(5):945-948. PubMed ID: 30176620
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large-scale pharmacovigilance analysis.
    Guo Q, Gao J, Guo H, Xie J, Cheng J.
    Int Immunopharmacol; 2023 Jan 18; 114():109490. PubMed ID: 36459923
    [Abstract] [Full Text] [Related]

  • 31. Successful treatment of nivolumab and ipilimumab triggered type 1 diabetes by using sodium-glucose transporter 2 inhibitor: a case report and systematic review.
    Fujiwara M, Shimizu M, Okano T, Maejima Y, Shimomura K.
    Front Public Health; 2023 Jan 18; 11():1264056. PubMed ID: 38106883
    [Abstract] [Full Text] [Related]

  • 32. Type 1 diabetes mellitus affected by potential toxicity from long-term use of nivolumab.
    Motomura Y, Urai S, Hirota Y, Takegawa N, Bando H, Yamamoto M, Fukuoka H, Tsuda M, Ogawa W.
    Diabetol Int; 2024 Jan 18; 15(1):130-134. PubMed ID: 38264226
    [Abstract] [Full Text] [Related]

  • 33. Salvage Ipilimumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma After Prior Immune Checkpoint Inhibitors.
    Gul A, Stewart TF, Mantia CM, Shah NJ, Gatof ES, Long Y, Allman KD, Ornstein MC, Hammers HJ, McDermott DF, Atkins MB, Hurwitz M, Rini BI.
    J Clin Oncol; 2020 Sep 20; 38(27):3088-3094. PubMed ID: 32491962
    [Abstract] [Full Text] [Related]

  • 34. Pregnancy and delivery in an advanced cancer survivor with immune checkpoint inhibitor-induced type 1 diabetes: a case report.
    Sugai K, Miwa T, Kojima J, Ueda Y, Tsukahara K, Nishi H, Suzuki R.
    Endocrine; 2024 Aug 20; 85(2):593-597. PubMed ID: 38502365
    [Abstract] [Full Text] [Related]

  • 35. Immune checkpoint inhibitor combination therapies very frequently induce secondary adrenal insufficiency.
    Manaka K, Sato J, Takeuchi M, Watanabe K, Kage H, Kawai T, Sato Y, Miyagawa T, Yamada D, Kume H, Sato S, Nagase T, Iiri T, Nangaku M, Makita N.
    Sci Rep; 2021 Jun 02; 11(1):11617. PubMed ID: 34078988
    [Abstract] [Full Text] [Related]

  • 36. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
    Appelbaum J, Wells D, Hiatt JB, Steinbach G, Stewart FM, Thomas H, Nghiem P, Kapur RP, Thompson JA, Bhatia S.
    J Immunother Cancer; 2018 Aug 31; 6(1):82. PubMed ID: 30170630
    [Abstract] [Full Text] [Related]

  • 37. Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC.
    Matsuura N, Koh G, Konishi C, Minamino S, Takahara Y, Harada H, Kodama K, Emoto M.
    Cancer Immunol Immunother; 2018 Sep 31; 67(9):1417-1424. PubMed ID: 29995236
    [Abstract] [Full Text] [Related]

  • 38. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
    Larkin J, Chmielowski B, Lao CD, Hodi FS, Sharfman W, Weber J, Suijkerbuijk KPM, Azevedo S, Li H, Reshef D, Avila A, Reardon DA.
    Oncologist; 2017 Jun 31; 22(6):709-718. PubMed ID: 28495807
    [Abstract] [Full Text] [Related]

  • 39. Fulminant Type 1 Diabetes Mellitus Accompanied by Positive Conversion of Anti-insulin Antibody after the Administration of Anti-CTLA-4 Antibody Following the Discontinuation of Anti-PD-1 Antibody.
    Shiba M, Inaba H, Ariyasu H, Kawai S, Inagaki Y, Matsuno S, Iwakura H, Yamamoto Y, Nishi M, Akamizu T.
    Intern Med; 2018 Jul 15; 57(14):2029-2034. PubMed ID: 29491310
    [Abstract] [Full Text] [Related]

  • 40. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
    Tan I, Malinzak M, Salama AKS.
    J Immunother Cancer; 2018 Jul 31; 6(1):77. PubMed ID: 30064495
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.